Skip to main content
Clinical Trials/NCT04753996
NCT04753996RecruitingNot Applicable

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

Mayo Clinic1 site in 1 country300 target enrollmentStarted: March 8, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
300
Locations
1
Primary Endpoint
Number of participants in study.

Study Overview

Brief Summary

The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.

Detailed Description

The study will ask participants to provide bile and/or bile duct cytology brushings at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). The bile and brushings will be used to generate and perpetuate bile-derived organoids using an established matrigel-based protocol. These organoids will then be used in downstream experiments to better understand disease-specific alterations to biological pathways informative of disease pathogenesis

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients diagnosed with PSC between the age of 18 and
  • The diagnosis of PSC will be based on standard PSC criteria including clinical and biochemical evidence of chronic cholestasis of at least six months duration, positive cholangiographic findings and compatible liver biopsies if available.
  • Women with PSC of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. Patients with PSC and Cholangiocarcinoma will be included.
  • Controls without history of PSC or evidence of other chronic liver disease of either gender that will participate in this study should be between the ages of 18-85.

Exclusion Criteria

  • Patients unable to provide inform consent.
  • Prisoners and institutionalized individuals.
  • PSC with orthotopic liver transplantation
  • History of Roux En Y procedure

Arms & Interventions

Primary Sclerosing Cholangitis (PSC)

Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).

Control (non-PSC)

Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).

Outcomes

Primary Outcomes

Number of participants in study.

Time Frame: 20 years

Number of participants in study.

Secondary Outcomes

  • Number of samples (per type)(20 years)
  • Number of clinical phenotypes and/or observations.(20 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Konstantinos N. Lazaridis, M.D.

Principal Investigator

Mayo Clinic

Study Sites (1)

Loading locations...

Similar Trials